2022
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial
Sposito A, Breder I, Barreto J, Breder J, Bonilha I, Lima M, Oliveira A, Wolf V, Luchiari B, do Carmo H, Munhoz D, Oliveira D, Coelho-Filho O, Coelho O, Matos-Souza J, Moura F, de Carvalho L, Nadruz W, Quinaglia T, Kimura-Medorima S. Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial. Cardiovascular Diabetology 2022, 21: 147. PMID: 35933413, PMCID: PMC9356512, DOI: 10.1186/s12933-022-01584-8.Peer-Reviewed Original ResearchConceptsFlow-mediated dilationEndothelial functionPost-treatment changesPlasma levelsPlasma levels of nitric oxide metabolitesBackgroundSodium-glucose cotransporter 2 inhibitorsCardiovascular eventsInhibitors reduce cardiovascular eventsLevels of nitric oxide metabolitesE groupPlasma levels of nitrateEE groupHigh-risk patientsProprotein convertase subtilisin/kexin 9Nitric oxide metabolitesRandomized active-controlled trialActive-controlled trialReduce cardiovascular eventsType 2 diabetesPCSK9-iSGLT2i treatmentPrimary endpointSGLT2-iEndothelial dysfunctionSecondary outcomes
2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R, Bonilha I, Oliveira D, Breder J, Cavalcante P, Moreira C, Moura F, de Lima-Junior J, do Carmo H, Barreto J, Nadruz W, Carvalho L, Quinaglia T. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology 2021, 20: 74. PMID: 33771149, PMCID: PMC8004411, DOI: 10.1186/s12933-021-01264-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzhydryl CompoundsBiomarkersBlood GlucoseBrazilCarotid Artery DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationEndothelium, VascularFemaleGlucosidesGlyburideGlycated HemoglobinHumansMaleMetforminMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeVasodilationConceptsFlow-mediated dilationSodium-glucose cotransporter-2 inhibitorsCoprimary endpointsAtherosclerotic diseaseWeeks of therapyResultsNinety-seven patientsMacrovascular endothelial functionCotransporter-2 inhibitorsType 2 diabetes mellitusRandomized active-controlled trialActive-controlled trialCarotid intima-media thicknessRandomized clinical trialsIntima-media thicknessDapagliflozin EffectGlibenclamide armsDapagliflozin groupArterial wall functionOpen-labelSGLT2i treatmentGlibenclamide groupResultsNinety-sevenSingle-centerMedian HbA1cCarotid atherosclerotic disease
2019
Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
Cintra R, Moura F, Carvalho L, Barreto J, Tambascia M, Pecoits-Filho R, Sposito A. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Revista Da Associação Médica Brasileira 2019, 65: 70-86. PMID: 30758423, DOI: 10.1590/1806-9282.65.1.70.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsRisk of hypoglycemiaAntidiabetic therapySodium-glucose co-transporter 2High risk of hypoglycemiaIncreased risk of hypoglycemiaPrevalence of type 2 diabetes mellitusType 2 diabetes mellitusRenal proximal convoluted tubulesChronic kidney diseaseCo-morbid diseasesSystolic blood pressurePost hoc studyProximal convoluted tubulesReduced insulin sensitivitySGLT2i therapyMedian ageSodium-glucoseSodium reabsorptionOlder individualsClinical trialsIncreased riskKidney diseaseBlood pressureConvoluted tubules
2017
Adverse outcome has a U-shaped relation with acute phase change in insulin sensitivity after ST-Elevation Myocardial Infarction
Moura F, Cintra R, Carvalho L, Santos S, Modolo R, Munhoz D, Quinaglia e Silva J, Coelho O, Nadruz W, Sposito A. Adverse outcome has a U-shaped relation with acute phase change in insulin sensitivity after ST-Elevation Myocardial Infarction. International Journal Of Cardiology 2017, 254: 16-22. PMID: 29246426, DOI: 10.1016/j.ijcard.2017.11.111.Peer-Reviewed Original ResearchConceptsST-elevation MIGRACE risk scoreInsulin sensitivity changesIntra-hospital deathMyocardial infarctionFollow-upMI hospitalizationAssociated with increased mortalityMarkers of glucose metabolismCox regression modelsInsulin provision therapyProspective cohortRisk scoreNet reclassification indexCardiac eventsAdverse cardiac eventsUpstream markersCox regressionAdverse outcomesHomeostasis model assessmentEstimate insulin sensitivityReclassification indexU-shaped relationStress hyperglycemiaInsulin sensitivity
2015
Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients
Moura F, Figueiredo V, Teles B, Barbosa M, Pereira L, Costa A, Carvalho L, Cintra R, Almeida O, Quinaglia e Silva J, Nadruz W, Sposito A, Study B. Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients. Atherosclerosis 2015, 243: 124-130. PMID: 26385505, DOI: 10.1016/j.atherosclerosis.2015.09.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood GlucoseBrachial ArteryCoronary AngiographyC-Reactive ProteinDiabetes MellitusDietEndothelium, VascularFemaleFollow-Up StudiesGlycated HemoglobinHumansInflammationMagnetic Resonance ImagingMaleMiddle AgedMyocardial InfarctionNitric OxidePatient AdmissionPercutaneous Coronary InterventionProspective StudiesRisk FactorsROC CurveSensitivity and SpecificityTreatment OutcomeConceptsST-elevation myocardial infarctionFlow-mediated dilationNon-diabetic STEMI patientsC-reactive proteinSTEMI patientsEndothelial functionFollow-upInflammatory responseLong-term risk of MACEIncident diabetesLower HbA1cMedian follow-upClinical follow-upDecreased endothelial functionNon-diabetic patientsRisk of MACEAdverse cardiac eventsAdverse clinical outcomesIncreased inflammatory responseROC curve analysisSudden cardiac deathMeasured plasma glucoseNon-fatal MIPercutaneous coronary interventionLong-term risk
2012
High-density lipoprotein levels are strongly associated with the recovery rate of insulin sensitivity during the acute phase of myocardial infarction: A study by euglycemic hyperinsulinemic clamp
Carvalho L, Martins N, Moura F, Cintra R, Almeida O, Quinaglia e Silva J, Sposito A, Group B. High-density lipoprotein levels are strongly associated with the recovery rate of insulin sensitivity during the acute phase of myocardial infarction: A study by euglycemic hyperinsulinemic clamp. Journal Of Clinical Lipidology 2012, 7: 24-28. PMID: 23351579, DOI: 10.1016/j.jacl.2012.10.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAge FactorsAgedBlood Chemical AnalysisFemaleGlucose Clamp TechniqueHospitalizationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistanceLipoproteins, HDLMagnetic Resonance ImagingMaleMiddle AgedMyocardial InfarctionSeverity of Illness IndexSex FactorsTreatment OutcomeTriglyceridesConceptsAcute phase of MIHigh HDL groupHDL groupHDL-CPhase of MIMyocardial infarctionEuglycemic hyperinsulinemic clampAcute phaseInsulin sensitivityIS indexAssociated with increased morbidityConsecutive nondiabetic patientsHyperinsulinemic clampLevels of HDL-CPlasma levels of HDL-CST-segment elevation MIHigh-density lipoprotein levelsLow HDL groupHigh-density lipoprotein (HDLHDL-C levelsPlasma HDL-CWaist circumferenceRate of ISDecrease of insulin sensitivityLipoprotein (HDL